Skip to main content
. 2018 May 16;8(5):180002. doi: 10.1098/rsob.180002

Figure 5.

Figure 5.

Selectivity of BH3-mimetic drugs under clinical investigation. Drugs specifically targeting BCL-2 (Venetoclax/ABT-199), BCL-2, BCL-XL and BCL-W (Navitoclax/ABT263) or MCL-1 (AMG176, S64315/MIK665) are now in clinical trial/use.